Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(Tyrphostin AG-1478; AG 1478; NSC 693255; AG1478)
AG-1478 Chemical Structure
|Product name: AG-1478|
|Cat. No.: HY-13524|
AG-1478 (NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM; almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.
IC50 Value: 3 nM 
in vitro: AG1478 inhibited EGFR phosphorylation in CNE2 cells without reduced expression of EGFR protein. The activation of Akt and MAPK which are downstream molecules of EGFR signaling pathway, were also inhibited by AG1478 . Although AG 1478 inhibited cell growth, DNA synthesis, EGFR tyrosine kinase activity, and receptor autophosphorylation of each cell line in a dose-dependent manner, it was significantly more potent in U87MG. delta EGFR cells than in the other two cell lines .
in vivo: At the lowest dose, plasma drug levels after the cessation of infusion declined with a half-life of approximately 43 min. EGFR activity, measured both by autophosphorylation and downstream signalling, was inhibited in a dose-dependent manner by injection of AG1478 in mice bearing xenografts of the human glioblastoma cell line U87MG .
|M.Wt||315.75||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO 25 mg/mL; Water <1 mg/mL; Ethanol 13 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||3.1671 mL||15.8353 mL||31.6706 mL|
|5 mM||0.6334 mL||3.1671 mL||6.3341 mL|
|10 mM||0.3167 mL||1.5835 mL||3.1671 mL|
AEE788(NVP-AEE 788) is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKC(alpha) and CDK1.
AG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 40 (mu)M.
AG-490 (Tyrphostin AG 490) is an inhibitor of EGFR with IC50 of 0.1 (mu)M, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1，which can be used to treat non-small cell lung cancer.
ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.
AZ-5104 is a potent EGFR inhibitor, displays potent antitumor activities both in vitro and in vivo.
AZD3759 is a potent, oral active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50 values were 0.3, 0.2, and 0.2 nM for EGFR TK wild-type, L858R mutant, and Exon 19Del enzymes, respectively.
BIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 (mu)M) and a range of other related tyrosine kinases (IC50 > 10 (mu)M).
BMS-690514 is a potent and selective inhibitor of epidermal growth factor receptor (EGFR), HER2, and HER4, as well as the VEGF receptor kinases.
Canertinib 2Hcl (CI-1033; PD-183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4.